SCM
RAPP

Soleus Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Soleus Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$313K Buy
+10,000
New +$281K 0.01% 88
2025
Q4 		– Sell
-80,000
Closed -$2.38M – 118
2025
Q3 		$2.38M Buy
+80,000
New +$1.43M 0.12% 71

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Soleus Capital Management's RAPP Position: Q1 2026 in Review

Soleus Capital Management opened a new position in Rapport Therapeutics (RAPP) in Q1 2026: 10,000 shares worth $313K. The stake represents 0.01% of the portfolio and ranks #88 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in RAPP as recently as Q3 2025.

Soleus Capital Management first reported a position in RAPP in Q3 2025 and has held it in 2 quarters since. The position peaked at $2.38M in Q3 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Soleus Capital Management held 10,000 shares of Rapport Therapeutics worth $313K as of Q1 2026.
  • Rapport Therapeutics was a new Soleus Capital Management position in Q1 2026.
  • Rapport Therapeutics made up 0.01% of Soleus Capital Management's portfolio in Q1 2026, its #88 holding.
  • Soleus Capital Management first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Soleus Capital Management's Rapport Therapeutics position peaked at $2.38M in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.